Silence Therapeutics plc (SLNCF)
USD 0.97
(21.25%)
USD 0.97
(21.25%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -49.6 Million GBP | -2.08% |
| 2022 | -48.59 Million GBP | -6.07% |
| 2021 | -45.81 Million GBP | -27.8% |
| 2020 | -35.84 Million GBP | -57.68% |
| 2019 | -22.73 Million GBP | -10.55% |
| 2018 | -20.56 Million GBP | -42.9% |
| 2017 | -14.39 Million GBP | -20.87% |
| 2016 | -11.9 Million GBP | -21.88% |
| 2015 | -9.76 Million GBP | 19.44% |
| 2014 | -12.12 Million GBP | -33.68% |
| 2013 | -9.07 Million GBP | 65.52% |
| 2012 | -26.31 Million GBP | -354.79% |
| 2011 | -5.78 Million GBP | 33.17% |
| 2010 | -8.65 Million GBP | -14.61% |
| 2009 | -7.55 Million GBP | 3.05% |
| 2008 | -7.79 Million GBP | -34.62% |
| 2007 | -5.78 Million GBP | -35.61% |
| 2006 | -4.26 Million GBP | -9.49% |
| 2005 | -3.89 Million GBP | -15.74% |
| 2004 | -3.36 Million GBP | -26.0% |
| 2003 | -2.67 Million GBP | -33.32% |
| 2002 | -2 Million GBP | 33.76% |
| 2001 | -3.02 Million GBP | -10.68% |
| 2000 | -2.73 Million GBP | -25.52% |
| 1999 | -2.17 Million GBP | -14.5% |
| 1998 | -1.9 Million GBP | 11.86% |
| 1997 | -2.15 Million GBP | -73.55% |
| 1996 | -1.24 Million GBP | -33.33% |
| 1995 | -933 Thousand GBP | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -18.32 Million GBP | -340.88% |
| 2024 Q1 | -4.15 Million GBP | 68.75% |
| 2023 FY | -49.6 Million GBP | -2.08% |
| 2023 Q2 | -11.45 Million GBP | 5.7% |
| 2023 Q4 | -13.29 Million GBP | -4.72% |
| 2023 Q1 | -12.14 Million GBP | -10.84% |
| 2023 Q3 | -12.69 Million GBP | -10.84% |
| 2022 FY | -48.59 Million GBP | -6.07% |
| 2022 Q2 | -14.08 Million GBP | -42.0% |
| 2022 Q3 | -13.62 Million GBP | 3.32% |
| 2022 Q1 | -9.92 Million GBP | 11.91% |
| 2022 Q4 | -10.96 Million GBP | 19.53% |
| 2021 Q2 | -12.92 Million GBP | -38.39% |
| 2021 FY | -45.81 Million GBP | -27.8% |
| 2021 Q1 | -9.34 Million GBP | 22.71% |
| 2021 Q3 | -12.28 Million GBP | 4.97% |
| 2021 Q4 | -11.26 Million GBP | 8.31% |
| 2020 Q2 | -7.09 Million GBP | 0.0% |
| 2020 FY | -35.84 Million GBP | -57.68% |
| 2020 Q1 | -7.09 Million GBP | -8.96% |
| 2020 Q3 | -9.56 Million GBP | -34.83% |
| 2020 Q4 | -12.08 Million GBP | -26.32% |
| 2019 Q1 | -4.85 Million GBP | 9.08% |
| 2019 FY | -22.73 Million GBP | -10.55% |
| 2019 Q2 | -4.85 Million GBP | 0.0% |
| 2019 Q3 | -6.51 Million GBP | -34.18% |
| 2019 Q4 | -6.51 Million GBP | 0.0% |
| 2018 Q1 | -4.94 Million GBP | -30.7% |
| 2018 Q3 | -5.33 Million GBP | -7.93% |
| 2018 Q2 | -4.94 Million GBP | 0.0% |
| 2018 FY | -20.56 Million GBP | -42.9% |
| 2018 Q4 | -5.33 Million GBP | 0.0% |
| 2017 Q3 | -3.78 Million GBP | -10.95% |
| 2017 Q1 | -3.41 Million GBP | -31.47% |
| 2017 Q2 | -3.41 Million GBP | 0.0% |
| 2017 Q4 | -3.78 Million GBP | 0.0% |
| 2017 FY | -14.39 Million GBP | -20.87% |
| 2016 Q3 | -2.59 Million GBP | 22.75% |
| 2016 FY | -11.9 Million GBP | -21.88% |
| 2016 Q1 | -3.35 Million GBP | -29.92% |
| 2016 Q2 | -3.35 Million GBP | 0.0% |
| 2016 Q4 | -2.59 Million GBP | 0.0% |
| 2015 Q1 | -2.29 Million GBP | 28.32% |
| 2015 Q2 | -2.29 Million GBP | 0.0% |
| 2015 Q4 | -2.58 Million GBP | 0.0% |
| 2015 Q3 | -2.58 Million GBP | -12.42% |
| 2015 FY | -9.76 Million GBP | 19.44% |
| 2014 FY | -12.12 Million GBP | -33.68% |
| 2014 Q4 | -3.2 Million GBP | 0.0% |
| 2014 Q3 | -3.2 Million GBP | -12.34% |
| 2014 Q2 | -2.85 Million GBP | 0.0% |
| 2014 Q1 | -2.85 Million GBP | -1.6% |
| 2013 FY | -9.07 Million GBP | 65.52% |
| 2013 Q4 | -2.81 Million GBP | 0.0% |
| 2013 Q1 | -1.72 Million GBP | 0.0% |
| 2013 Q2 | -1.72 Million GBP | 0.0% |
| 2013 Q3 | -2.81 Million GBP | -62.88% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 FY | -26.31 Million GBP | -354.79% |
| 2011 FY | -5.78 Million GBP | 33.17% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 Q2 | - GBP | 0.0% |
| 2010 FY | -8.65 Million GBP | -14.61% |
| 2009 FY | -7.55 Million GBP | 3.05% |
| 2009 Q2 | - GBP | 0.0% |
| 2008 Q2 | - GBP | 0.0% |
| 2008 FY | -7.79 Million GBP | -34.62% |
| 2007 FY | -5.78 Million GBP | -35.61% |
| 2007 Q2 | - GBP | 0.0% |
| 2006 FY | -4.26 Million GBP | -9.49% |
| 2006 Q2 | - GBP | 0.0% |
| 2005 FY | -3.89 Million GBP | -15.74% |
| 2005 Q2 | - GBP | 0.0% |
| 2004 Q2 | - GBP | 0.0% |
| 2004 FY | -3.36 Million GBP | -26.0% |
| 2003 FY | -2.67 Million GBP | -33.32% |
| 2003 Q2 | - GBP | 0.0% |
| 2002 FY | -2 Million GBP | 33.76% |
| 2001 FY | -3.02 Million GBP | -10.68% |
| 2000 FY | -2.73 Million GBP | -25.52% |
| 1999 FY | -2.17 Million GBP | -14.5% |
| 1998 FY | -1.9 Million GBP | 11.86% |
| 1997 FY | -2.15 Million GBP | -73.55% |
| 1996 FY | -1.24 Million GBP | -33.33% |
| 1995 FY | -933 Thousand GBP | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ContraFect Corporation | -56.88 Million USD | 12.806% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 30.9% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 1109.276% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -18852.645% |
| SQZ Biotechnologies Company | -75.82 Million USD | 34.581% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -1640.182% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -177.94% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 160.602% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -3129.324% |
| Marizyme, Inc. | -34.08 Million USD | -45.524% |
| Genus plc | 6.4 Million USD | 875.063% |
| Pharming Group N.V. | -4.87 Million USD | -916.57% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -2397.082% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -5225.861% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -494.06% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -3438.111% |
| IMV Inc. | -38.67 Million USD | -28.27% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -1703.232% |
| ONE Bio Corp. | 13.68 Million USD | 462.561% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 15.911% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -12633.013% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -1787.862% |
| Biomind Labs Inc. | -1 Million USD | -4813.218% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 9.766% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -646.148% |
| Skye Bioscience, Inc. | -13.67 Million USD | -262.82% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -2560.631% |
| Mesoblast Limited | -84.14 Million USD | 41.051% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -165511.645% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -883.332% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -212.57% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -2466.684% |
| GB Sciences, Inc. | -1.42 Million USD | -3391.988% |
| MultiCell Technologies, Inc. | -722.81 USD | -6862561.004% |
| Alpha Cognition Inc. | -9.7 Million USD | -411.086% |
| HST Global, Inc. | -140.9 Thousand USD | -35103.361% |
| CSL Limited | 3.7 Billion USD | 101.34% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Agentix Corp. | -1.37 Million USD | -3516.095% |
| Halberd Corporation | -75.05 Thousand USD | -65994.604% |
| Enzolytics Inc. | -2.14 Million USD | -2208.451% |
| Resverlogix Corp. | -12.74 Million USD | -289.081% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -1465.647% |
| argenx SE | -425.04 Million USD | 88.33% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -4651.341% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 1501.243% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -1356.808% |
| Bioxytran, Inc. | -3.82 Million USD | -1198.484% |
| Zenith Capital Corp. | -8.94 Million USD | -454.668% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -1920.269% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -28822.006% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -2374.315% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Genscript Biotech Corporation | -415.79 Million USD | 88.07% |
| Kadimastem Ltd | -3.04 Million USD | -1531.576% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -4940.785% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -1609.746% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -3849.363% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 609.153% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -989.067% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -1224.038% |
| EV Biologics, Inc. | -483.06 Thousand USD | -10168.661% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -27232.286% |
| Q BioMed Inc. | -3.44 Million USD | -1339.626% |
| LadRx Corporation | -3.82 Million USD | -1197.303% |
| Cell Source, Inc. | -4.32 Million USD | -1046.822% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -11838.991% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -7120.904% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 10.636% |
| Itoco Inc. | -919.14 Thousand USD | -5296.784% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -1070.343% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -4309.613% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -1599.091% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -4332.887% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -3040.776% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 6.69 Million USD | 841.146% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -284636.812% |
| NovAccess Global Inc. | -2.46 Million USD | -1910.897% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -196975.884% |
| BioStem Technologies, Inc. | -7.77 Million USD | -537.668% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -22439.282% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -3614.456% |
| Qrons Inc. | -643.67 Thousand USD | -7606.35% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -8683.775% |
| SYBLEU INC | -149.18 Thousand USD | -33151.106% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -2124.515% |
| Rebus Holdings, Inc. | -664 Thousand USD | -7370.482% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -7120.904% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -2631.017% |
| Affymax, Inc. | -15.04 Million USD | -229.682% |
| Mobile Lads Corp. | -554.55 Thousand USD | -8844.91% |
| International Stem Cell Corporation | -663 Thousand USD | -7381.75% |
| CytoDyn Inc. | -18.05 Million USD | -174.693% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -94132.523% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -243774.14% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -36.778% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -2965.76% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -6641.185% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -1494.471% |
| Neutra Corp. | -229.48 Thousand USD | -21515.262% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -182.821% |
| PureTech Health plc | -146.19 Million USD | 66.071% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -130.812% |
| IXICO plc | -1.43 Million USD | -3351.914% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -422.643% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 59.276% |
| CSL Limited | 3.81 Billion USD | 101.301% |
| Cellectis S.A. | -108.85 Million USD | 54.432% |